WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Revenue of WuXi Biologics (Cayman) Inc. (WXXWY)
Revenue in 2023 (TTM): $17.03 B
According to WuXi Biologics (Cayman) Inc.'s latest financial reports the company's current revenue (TTM) is $17.03 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of WuXi Biologics (Cayman) Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $17.03 B | $6.83 B | $5.71 B | $4.17 B | $3.4 B |
| 2022 | $15.27 B | $6.72 B | $5.07 B | $5.36 B | $4.42 B |
| 2021 | $10.29 B | $4.83 B | $3.62 B | $3.99 B | $3.39 B |
| 2020 | $5.61 B | $2.53 B | $1.77 B | $1.97 B | $1.69 B |
| 2019 | $3.98 B | $1.66 B | $1.14 B | $1.13 B | $1.01 B |
| 2018 | $2.53 B | $1.02 B | $663.91 M | $737.72 M | $630.59 M |
| 2017 | $1.62 B | $660.56 M | $498.17 M | $303.69 M | $252.63 M |
| 2016 | $989.03 M | $389.11 M | $325.07 M | $175.85 M | $141.1 M |
| 2015 | $557.04 M | $180.72 M | $124.94 M | $65.4 M | $44.51 M |
| 2014 | $331.85 M | $123.25 M | $93.88 M | $49.01 M | $41.98 M |